{{distinguish|cinazepam|clonazepam|camazepam}}

{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 447551787
| IUPAC_name = (''RS'')-3-[9-Chloro-6-(2-fluorophenyl)-4-hydroxy-3-oxo-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-2-yl]propanenitrile
| image = Cinolazepam.svg
| width = 190
| image2 = Cinolazepam3d.png
| width2 = 180
| chirality = [[Racemic mixture]]
<!--Clinical data-->
| tradename = Gerodorm
| Drugs.com = {{drugs.com||cinolazepam}}
| pregnancy_category = 
| legal_US = Schedule IV
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 90â€“100%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 9 hours<ref name=half-life>{{cite journal | first = B. | last = Saletu |author2=G. Kindshofer |author3=P. Anderer |author4=J. Grunberger  | year = 1987 | title = Short-term sleep laboratory studies with cinolazepam in situational insomnia induced by traffic noise. | journal = International Journal of Clinical Pharmacology Research | volume = 7 | issue = 5 | pages = 407&ndash;18 | pmid = 2889679}}</ref>
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 75696-02-5
| ATC_prefix = N05
| ATC_suffix = CD13
| PubChem = 3033621
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01594
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2298251
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 68P0556B0U
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07328
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2104926
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 59514

<!--Chemical data-->
| C=18 | H=13 | Cl=1 | F=1 | N=3 | O=2
| molecular_weight = 357.8
| smiles = FC1=CC=CC=C1C2=NC(C(N(CCC#N)C3=C2C=C(C=C3)Cl)=O)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H13ClFN3O2/c19-11-6-7-15-13(10-11)16(12-4-1-2-5-14(12)20)22-17(24)18(25)23(15)9-3-8-21/h1-2,4-7,10,17,24H,3,9H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XAXMYHMKTCNRRZ-UHFFFAOYSA-N
}}

'''Cinolazepam'''<ref> US Patent 4388313 Novel 3-hydroxy-1,4-benzodiazepine-2-ones and process for the preparation thereof</ref> (marketed under the brand name '''Gerodorm''')<ref name=Gerodorm>{{cite web|url=http://www.lannacher.ro/gerodorm.html |title=Gerodorm |accessdate=17 August 2006 |author=Lannacher Romania |year=1999 |work=Produse Gerot inregistrate in Romania |language=Romanian |archiveurl=https://web.archive.org/web/20061011022835/http://www.lannacher.ro/gerodorm.html |archivedate=11 October 2006 |deadurl=yes |df= }}</ref> is a drug which is a [[benzodiazepine]] derivative. It possesses [[anxiolytic]], [[anticonvulsant]], [[sedative]] and [[skeletal muscle relaxant]] properties.
Due to its strong sedative properties, it is primarily used as a [[hypnotic]].

Cinolazepam is not approved for sale in the United States or Canada.

==See also==
*[[Benzodiazepine]]

==References==
{{Reflist}}

==External links==
* [http://www.inchem.org/documents/pims/pharm/pim920.htm Inchem.org - Cinolazepam]

{{Benzodiazepines}}
{{Hypnotics and sedatives}}
{{GABAAR PAMs}}

[[Category:Alcohols]]
[[Category:Benzodiazepines]]
[[Category:Chloroarenes]]
[[Category:Fluoroarenes]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Hypnotics]]
[[Category:Lactams]]
[[Category:Nitriles]]

{{sedative-stub}}